SCHEMBL4187130

SCHEMBL4187130

CC(C)(Sc1ccc(OCCc2ccc(Cl)cc2Cl)cc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.47
NR4A2 P43354 2/20 0.46
PPARA Q07869 4/20 0.42
PPARD Q03181 2/20 0.42
PPARG P37231 2/20 0.42
NPC1 O15118 1/20 0.41
ACLY P53396 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TRPV1 Q8NER1 1/20 0.39
IDO1 P14902 1/20 0.39
S1PR4 O95977 1/20 0.39
S1PR1 P21453 1/20 0.39
LTK P29376 1/20 0.39
TAOK1 Q7L7X3 1/20 0.39
S1PR5 Q9H228 1/20 0.39
NR4A1 P22736 1/20 0.39
NR4A3 Q92570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3381537 0.89 BCL2 (0.43) BCL2NR4A2NPC1MEN1KMT2A
SCHEMBL4184977 0.88 BCL2 (0.47) BCL2NR4A2PPARAPPARDPPARG
SCHEMBL4194987 0.88 NR4A2 (0.46) BCL2NR4A2ACLYMEN1KMT2A
SCHEMBL4192083 0.83 PPARA (0.59) PPARAPPARDPPARGKMT2A
SCHEMBL3384706 0.77 F10 (0.43) BCL2NR4A2NPC1MEN1KMT2A
SCHEMBL4192840 0.76 NR4A2 (0.44) BCL2NR4A2PPARAPPARGACLY
SCHEMBL11538993 0.74 PPARA (0.51) PPARAPPARGMEN1KMT2A
SCHEMBL4398676 0.73 PPARA (0.51) PPARAPPARGMEN1KMT2A
SCHEMBL3382165 0.73 PPARG (0.49) PPARAPPARDPPARG
SCHEMBL6066439 0.72 NR4A2 (0.58) BCL2NR4A2MEN1KMT2ATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572180-B1 USE OF ALPHA-PHENYLTHIOCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY SIGMA TAU IND FARMACEUTI (IT) 2009-02-25 EP claimed
US-7375124-B2 Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-05-20 US claimed
US-20080027098-A1 Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-01-31 US claimed
US-20060154979-A1 Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity SIGMA-TAU INDUSTRE FARMACEUTICHE RIUNITE S.P.A. (IT) 2006-07-13 US claimed
EP-1572180-A1 USE OF a-PHENYLTHIOCARBOXYLIC AND a-PHENYLOXYCARBOXYLIC A CIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2005-09-14 EP claimed
WO-2004056355-A1 USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2004-07-08 WO claimed
EP-1572180-B1 USE OF ALPHA-PHENYLTHIOCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY SIGMA TAU IND FARMACEUTI (IT) 2009-02-25 EP disclosed
US-7375124-B2 Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-05-20 US disclosed
US-20060154979-A1 Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity SIGMA-TAU INDUSTRE FARMACEUTICHE RIUNITE S.P.A. (IT) 2006-07-13 US disclosed
EP-1572180-A1 USE OF a-PHENYLTHIOCARBOXYLIC AND a-PHENYLOXYCARBOXYLIC A CIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2005-09-14 EP disclosed
WO-2004056355-A1 USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027098-A1 Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation PPARA, PPARD, PPARG BCL2 1723/4885NR4A2 356/4885PPARA 1/4885
US-20060154979-A1 Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity LIPC, HMGCR, PNLIP BCL2 685/4885NR4A2 2552/4885PPARA 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.